Collaboration allows Agilent to use IDBS's ChemIQ and ChemXtra technologies to provide chemical intelligence for Agilent Synapsia informatics workbench
IDBS, a supplier of data management software for the life sciences, and Agilent Technologies have announced a license agreement.
The collaboration allows Agilent to use IDBS's ChemIQ and ChemXtra technologies to provide chemical intelligence for Agilent Synapsia informatics workbench, a suite of software tools designed to help scientists synthesise and share research. The integration of ChemIQ and ChemXtra into Synapsia enables it to bridge the data domains of biology and chemistry, facilitating a more efficient, multi-disciplinary approach to drug discovery and development.
The IDBS ChemXtra data cartridge gives Synapsia advanced chemical searching and indexing capabilities.
The IDBS ChemIQ cheminformatics software development kit enables Synapsia users to collect, display and manipulate structural information. With ChemIQ and ChemXtra, scientists can now store and query compound information in Synapsia projects.
The compound data can be imported into Synapsia from other chemical databases or from mol files and SD files.
The chemical information can be searched by structure and can be associated with various 'omics' data and relevant information in a project-focused approach, helping researchers connect disparate data, annotate information and share findings with colleagues.
"Synapsia is a unique application for the generation of knowledge from information and data," said Neil Kipling, chairman and CEO of IDBS.
"We are very pleased to license ChemXtra and ChemIQ to Agilent, providing the cheminformatics power behind Synapsia". "The IDBS technologies provide the chemical intelligence our customers need in an intuitive and rapidly implemented system," said Francois Mandeville, business manager for Agilent's informatics solutions business.
"This collaboration helps Synapsia users bring together chemical and biological data in the context of projects and will significantly improve how researchers work".
Agilent Synapsia is a portfolio of software products for optimising the drug discovery and development process.
It enables the building of a context layer that associates heterogeneous data from abundant information sources in each project.
Synapsia allows scientists to take a project-oriented approach to data analysis and review, which improves decision quality and integrity, and facilitates the development of intellectual property.
